Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2011 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Other Non Operating Income for 16 consecutive years, with $260000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income rose 106.23% year-over-year to $260000.0; the trailing twelve-month figure through Jun 2026 stood at -$14.4 million (down 207.16% YoY), and the FY2025 full-year result was -$17.3 million, down 2603.9% from the prior year.
• Other Non Operating Income grew to $260000.0 in Q2 2026 per BCRX's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $260000.0 in Q2 2026 and bottomed at -$29.0 million in Q2 2023.
• Historically, Other Non Operating Income has averaged -$3.0 million across 5 years, with a median of -$538000.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income surged 198.51% in 2022, then tumbled 146300.0% in 2026.
• Over 5 years, Other Non Operating Income stood at -$1.4 million in 2022, then jumped by 47.36% to -$737000.0 in 2023, then climbed by 18.05% to -$604000.0 in 2024, then sank by 1625.33% to -$10.4 million in 2025, then surged by 102.49% to $260000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $260000.0, -$1.5 million, and -$10.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.